Rising incidence, no change in survival and decreasing mortality from thyroid cancer in The Netherlands since 1989

Olga Husson1,2, Harm R Haak3, Liza N van Steenbergen2, Willy-Anne Nieuwlaat4, Boukje A C van Dijk5, Grard A P Nieuwenhuijzen6, Henrike Karim-Kos7, Johannes L Kuipmans8, Lonneke V van de Poll-Franse1,2 and Jan Willem W Coebergh2,7

1Department of Medical Psychology and Neuropsychology, Center of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University, Warandelaan 2, PO Box 90153, 5000 LE Tilburg, The Netherlands
2Comprehensive Cancer Centre South (CCCS), Eindhoven Cancer Registry, Eindhoven, The Netherlands
3Maxima Medisch Centrum Eindhoven, Department of Endocrinology, Eindhoven, The Netherlands
4Department of Endocrinology, Elisabeth Hospital Tilburg, Tilburg, The Netherlands
5Department of Registry and Research, Comprehensive Cancer Centre the Netherlands (IKNL), Utrecht, The Netherlands
6Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands
7Department of Public Health, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands
8VGZ Health Insurance Company, Eindhoven, The Netherlands

Correspondence should be addressed to O Husson
Email o.husson@tilburguniversity.edu

Abstract

The incidence of thyroid cancer (TC) is increasing worldwide, partly due to increased detection. We therefore assessed combined trends in incidence, survival and mortality of the various types of TC in The Netherlands between 1989 and 2009. We included all patients ≥15 years with TC, diagnosed in the period 1989–2009 and recorded in The Netherlands Cancer Registry (n=8021). Information on age, gender, date of diagnosis, histological type of tumour and tumour–node–metastasis classification was recorded. Mortality data (up to 1st January 2010) were derived from Statistics Netherlands. Annual percentages of change in incidence, mortality and relative survival were calculated. Since 1989 the incidence of TC increased significantly in The Netherlands (estimated annual percentage change (EAPC)=+1.7%). The incidence rates increased for all age groups (except for females >60 years), papillary tumours (EAPC=+3.5%), T1 and T3 TC (EAPC=+7.9 and +5.8% respectively). Incidence rates decreased for T4 TC (−2.3%) and remained stable for follicular, medullary anaplastic and T2 TC. Five-year relative survival rates remained stable for papillary (88%) and follicular (77%) TC, all age groups and T1–T3 TC (96, 94 and 80% respectively) and somewhat lower for T4 (53%), medullary (65%) and anaplastic TC (5%) in the 2004–2009 period compared with earlier periods. Mortality due to TC decreased (EAPC=−1.9%). TC detection and incidence has been rising in The Netherlands, while mortality rates are decreasing and survival rates remained stable or slightly decreasing.

Key Words
thyroid carcinoma
incidence
mortality
time trends
survival
histology

Endocrine-Related Cancer (2013) 20, 263–271
Introduction

In recent years, the incidence of thyroid cancer (TC) has increased in the USA and most European countries (Davies & Welch 2006, Ferlay et al. 2010). TC is the most common endocrine malignancy (van der Zwan et al. 2012). The higher incidence rates are often attributed to increased environmental radiation exposure (Cardis et al. 2006), radiation therapy for the treatment of the head and neck areas (Schneider & Sarne 2005), lower iodine intake (Ceresini et al. 2012) or higher prevalence of obesity (Kitahara et al. 2011). However, the exact aetiology of TC remains unclear. It is also suggested that increasing use of more precise diagnostic imaging might contribute to an increased identification of subclinical disease (Davies & Welch 2006, Kent et al. 2007). Although a larger portion of small tumours then appear to have been detected, slightly increased incidence rates of larger tumours are also observed (Kent et al. 2007). Contrary to the increasing incidence, mortality from TC remained stable in North America (Davies & Welch 2006) and decreased (−23 and −28%, for men and women respectively) in the European Union (Pacini et al. 2010) and prognosis is good (except for the anaplastic type of tumour).

The combined measurements of TC burden (i.e. incidence, mortality and survival) could indicate whether and where progress had been made in cancer diagnosis and treatment and where improvements might be needed. As none of the previous studies described all three determinants of TC burden in combination, we assessed long-term trends in incidence, mortality and survival of TC in The Netherlands between 1989 and 2009. We hypothesised that in the absence of a clear pattern of aetiological/environmental exposures the rising incidence might be largely due to increased diagnostic scrutiny, leading to an increased detection of small tumours. If the incidence of small tumours would increase, due to its excellent prognosis, we expect the overall survival rates to increase.

Materials and methods

Data collection

Population-based data were used from the nationwide Netherlands Cancer Registry (NCR), which was started in 1989 and combines data from eight Dutch regional cancer registries, currently merged into two. The NCR is based on notification of all new diagnosed malignancies in The Netherlands by the pathological anatomical national automated archive (PALGA), supplemented by notifications from the national registry of hospital discharge, various clinical chemistry laboratories and radiotherapy institutions. Information on patient (sex, date of birth) and tumour characteristics (date of diagnosis, histology, Table 1

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>n = 437</td>
<td>n = 504</td>
<td>n = 542</td>
<td>n = 858</td>
<td>n = 1149</td>
<td>n = 1188</td>
<td>n = 1335</td>
<td>n = 2008</td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>&lt;45</td>
<td>164 (38)</td>
<td>172 (34)</td>
<td>178 (33)</td>
<td>271 (32)</td>
<td>456 (40)</td>
<td>470 (40)</td>
<td>572 (43)</td>
<td>778 (39)</td>
</tr>
<tr>
<td>45–59</td>
<td>121 (28)</td>
<td>131 (26)</td>
<td>155 (29)</td>
<td>250 (29)</td>
<td>222 (19)</td>
<td>279 (23)</td>
<td>313 (23)</td>
<td>528 (26)</td>
</tr>
<tr>
<td>60–74</td>
<td>100 (23)</td>
<td>124 (25)</td>
<td>125 (23)</td>
<td>227 (26)</td>
<td>298 (26)</td>
<td>257 (22)</td>
<td>244 (18)</td>
<td>383 (19)</td>
</tr>
<tr>
<td>≥75</td>
<td>52 (12)</td>
<td>77 (15)</td>
<td>84 (15)</td>
<td>110 (13)</td>
<td>173 (15)</td>
<td>182 (15)</td>
<td>206 (15)</td>
<td>319 (16)</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papillary carcinoma</td>
<td>213 (49)</td>
<td>261 (52)</td>
<td>306 (56)</td>
<td>529 (62)</td>
<td>604 (53)</td>
<td>684 (58)</td>
<td>846 (63)</td>
<td>1359 (68)</td>
</tr>
<tr>
<td>Follicular carcinoma</td>
<td>108 (25)</td>
<td>113 (22)</td>
<td>114 (21)</td>
<td>173 (20)</td>
<td>311 (27)</td>
<td>272 (23)</td>
<td>280 (21)</td>
<td>352 (18)</td>
</tr>
<tr>
<td>Medullary carcinoma</td>
<td>62 (14)</td>
<td>73 (14)</td>
<td>57 (11)</td>
<td>90 (10)</td>
<td>80 (7)</td>
<td>91 (8)</td>
<td>69 (5)</td>
<td>95 (5)</td>
</tr>
<tr>
<td>Anaplastic carcinoma</td>
<td>18 (4)</td>
<td>29 (5)</td>
<td>35 (6)</td>
<td>32 (4)</td>
<td>71 (6)</td>
<td>73 (6)</td>
<td>78 (6)</td>
<td>108 (5)</td>
</tr>
<tr>
<td>Other</td>
<td>36 (8)</td>
<td>28 (6)</td>
<td>30 (6)</td>
<td>34 (4)</td>
<td>83 (7)</td>
<td>68 (6)</td>
<td>62 (5)</td>
<td>94 (5)</td>
</tr>
<tr>
<td>T factor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>54 (12)</td>
<td>80 (16)</td>
<td>89 (16)</td>
<td>249 (29)</td>
<td>164 (14)</td>
<td>174 (15)</td>
<td>258 (19)</td>
<td>731 (36)</td>
</tr>
<tr>
<td>2</td>
<td>151 (35)</td>
<td>147 (29)</td>
<td>170 (31)</td>
<td>168 (20)</td>
<td>457 (40)</td>
<td>508 (43)</td>
<td>541 (41)</td>
<td>506 (25)</td>
</tr>
<tr>
<td>3</td>
<td>56 (13)</td>
<td>69 (14)</td>
<td>87 (16)</td>
<td>233 (27)</td>
<td>124 (11)</td>
<td>140 (12)</td>
<td>160 (12)</td>
<td>392 (20)</td>
</tr>
<tr>
<td>4</td>
<td>96 (22)</td>
<td>105 (21)</td>
<td>107 (20)</td>
<td>120 (14)</td>
<td>242 (21)</td>
<td>219 (18)</td>
<td>238 (18)</td>
<td>239 (12)</td>
</tr>
<tr>
<td>X</td>
<td>80 (18)</td>
<td>101 (20)</td>
<td>89 (16)</td>
<td>83 (10)</td>
<td>161 (14)</td>
<td>144 (12)</td>
<td>137 (10)</td>
<td>133 (7)</td>
</tr>
</tbody>
</table>

*Six-year period.
location, T factor (tumour–node–metastasis (TNM) classification; Hermanek & Sobin 1987, Sobin & Fleming 1997, Wittekind et al. 2002) was routinely obtained from the medical records 6–12 months after diagnosis.

Vital status was actively obtained on a regular basis from the municipal registries and from the database of deceased persons of the Central Bureau for Genealogy (date of last follow-up: 1st January 2010). Survival time was calculated as the time from diagnosis to death or to 1st January 2010 or to date of emigration.

Topography and histology were coded according to the International Classification of Diseases for Oncology (ICD-O-3; Fritz et al. 2000). All tumours with an ICD-O-3 topography code thyroid (C73) diagnosed in the period 1989–2009 were included in this study (n=8021). The following histological categories were used: papillary cancer (morphology codes 8050, 8201, 8260, 8340–8344, 8350, 8504), follicular cancer (8290, 8330–8332, 8335), medullary cancer (8345, 8510–8512), anaplastic cancer (8020–8035) and other carcinomas. T factor was based on pathological T stage. For cases where pathological stage was unknown, clinical stage was used. The TNM classification changed significantly during the study period. Classification was based on the fourth edition for study period 1989–1997; fifth edition 1998–2002 and sixth edition after 2002 (Hermanek & Sobin 1987, Sobin & Fleming 1997, Wittekind et al. 2002).

Patients <15 and >95 years were excluded from the survival analysis, as well as cases diagnosed at autopsy. Age at diagnosis was divided into two groups (≤60 and >60 years). The study period was divided into three categories of 5 years and one of 6 years: 1989–1993, 1994–1998, 1999–2003 and 2004–2009. Incidence rates were calculated per age group, sex, histological type and T factor.

**Statistical analyses**

Annual incidence and mortality rates for the period 1989–2009 were calculated per 100 000 person-years, using the mid-year population size as obtained from Statistics Netherlands. Rates were age-standardised to the European standard population (European standardised rates (ESR)). Trends in incidence were evaluated by calculating the estimated annual percentage change (EAPC) and the corresponding 95% CI. To calculate this, a regression line was fitted to the natural logarithm of the rates, using the calendar year as regressor variable (i.e. \( y = ax + b \), where \( y = \ln \text{(rate)} \) and \( x = \text{calendar year} \), then \( \text{EAPC} = 100 \times (e^a - 1) \)). This calculation assumes that the rates increased or decreased at a constant rate over the entire period. Joinpoint analyses were performed to discern significant changes in the trend and, if present, when they occurred (Kim et al. 2000).

Relative survival was used as an estimation of disease-specific survival. It was derived as the ratio of observed survival of the cancer patients and the expected survival of a comparable age- and sex-matched group of the general population while using the Ederer method (Ederer & Heise 1959). Cohort-based, relative survival analysis was used to calculate 5-year relative survival.

Survival trends were quantified as the mean period percentage change within the period 1989–2009 estimated by a linear regression model. A positive value of the mean period change implies an upward trend in survival.
Multivariate relative survival analyses, using Poisson regression modelling, were carried out to estimate relative excess risk (RER) of dying adjusted for follow-up interval and age group. SAS Software (SAS System 9.2; SAS Institute, Cary, NC, USA) was used to perform the statistical analyses.

**Results**

**Trends in incidence**

In The Netherlands 8021 new TC cases were registered between 1989 and 2009. Mean age at diagnosis was 53 ± 19 (s.d.) years. The female to male ratio was 2.4:1. The proportion of male patients <45 years decreased steadily from 38% in 1989–1993 to 32% in 2004–2009. In females, 40% were <45 years of age at diagnosis. Furthermore, the proportion of patients 45–59 years increased (Table 1).

The overall incidence rate increased from 2.0 in 1989 to 2.9 per 100 000 person-years in 2009 (EAPC = +1.7%; 95% CI 1.2–2.3), corresponding to an increase from 315 cases in 1989 to 537 in 2009. For females the incidence rate increased from 3.1 in 1989 to 4.1 per 100 000 person-years in 2009 (EAPC = +1.7%; 95% CI 1.1–2.4). The EAPC for females changed from +0.1% (95% CI −0.9 to 1.2) before 2001 to +4.7% (95% CI 2.7–6.7) after 2001. For males the incidence rate increased from 1.0 in 1989 to 1.7 per 100 000 person-years in 2009 (EAPC = +1.6%; 95% CI 1.2–2.3). Incidence rates increased for all age groups, except for females ≥60 years (Fig. 1).

The percentage of papillary TC cases increased for males from 49% in 1989 to 62% in 2009 and for females from 53% in 1989 to 68% in 2009 (P < 0.01; Table 1). The overall incidence rate increased for papillary TC from 1.1 in 1989 to 2.1 per 100 000 person-years in 2009 (EAPC = +3.5%; 95% CI 2.4–4.6). For females, the EAPC for papillary TC changed from 0.0% (95% CI −2.6 to 2.7) before 1996 to +5.0% (95% CI 3.9–6.1) after 1996 (Fig. 2). The incidence of follicular, medullary and anaplastic TC remained relatively stable for both sexes (Fig. 2).

For T1 TC, the incidence rate increased from 0.2 in 1989 to 1.1 per 100 000 person-years in 2009 (EAPC = +7.9%; 95% CI 5.8–10.0) and for T3 TC the incidence rate increased from 0.2 in 1989 to 0.7 per 100 000 person-years in 2009 (EAPC = +5.8%; 95% CI 4.1–7.6). The EAPC for T1 TC changed from +2.1% (95% CI −1.3 to 5.6) before 2002 to +14.3% (95% CI 3.5–26.3) after 2002 and for T3 TC it changed from +0.2% (95% CI −2.6 to 3.1) before 2002 to +9.5% (95% CI 5.9–13.1) after 2002, these joinpoints were only found for females (Fig. 3). The overall incidence rate of T2 TC remained stable from 0.8 in 1989 to 0.7 per 100 000 person-years in 2009 (EAPC = −1.1%; 95% CI −2.2 to 0.0). For females, the EAPC for T2 TC changed from +1.6% (95% CI 0.2–3.0) before 2002 to +3.9% (95% CI 3.5–26.3) after 2003 (with and decrease of −49.6% between 2002 and 2003 due to the change in TNM classification; Fig. 3). This trend was not found for males (EAPC = −1.3% (95% CI −3.4 to 0.9)). The incidence rate for T4 TC decreased by −2.3% (95% CI −3.3 to 1.4) per year between 1989 and 2009; and changed from −0.2% (95% CI −2.4 to 2.0) before 2002 to −2.4% (95% CI −5.6 to 1.0) after 2002.
was seen in survival of T1, T2 and T3 TC, while survival from T4 TC appeared to decrease over time. Five-year survival rates remained more or less stable for papillary TC (∼88%) and follicular TC (∼77%) over the entire study period and appeared to decrease slightly for medullary TC from 64 to 61% in 2004–2009. The 1-year relative survival for anaplastic TC decreased from 18% in 1989–1993 to 14% in 2004–2009.

Multivariable relative survival analyses showed an increased risk of death for older patients, patients with a higher T factor and follicular, anaplastic or medullary tumour type, however no effect for period was found (Table 3).

Trends in mortality

Mortality decreased with −1.9% (95% CI −2.8 to 0.9) per year between 1989 and 2009 (Fig. 4), more in males (−2.2%) than in females (−1.7%). In absolute numbers we observed a slight increase from 98 deaths in 1989 to 105 deaths in 2009.

Discussion

Our study shows that since 1989 the incidence of TC increased significantly in The Netherlands, while mortality from TC decreased. This increase was due to papillary tumours only. The overall 5-year relative survival remained stable and appeared to be somewhat higher for both sexes, all age groups and T1–T3 TC and somewhat lower for T4, medullary and anaplastic TC in the period 2004–2009 compared with earlier periods.

The rising age-standardised incidence of TC in The Netherlands is in concordance with patterns observed in many other European countries and the USA (Ferlay et al. 2010). The increase in our study was mainly due to the increased number of detected small tumours (T1) of papillary histological subtype. This shift to the detection of more T1 papillary tumours can partly be explained by the change in TNM classification in 2002, however the T1 TC incidence rates were already increasing before 2002 (Kuijpens et al. 1998) and incidence rates for T2 TC were also increasing after 2002. The incidence rates started to increase at a younger age in women than in men, possibly related to greater use of health care services by young and middle-aged women compared with men of the same age (Dal Maso et al. 2011). Also, the incidence rate of papillary TC increased more steeply among women (starting around 2001) than men, likely
because of the higher number of biopsies performed in this population (Netea-Maier et al. 2008).

The main question debated in the literature is whether or not the observed increase in TC incidence is the result of a real increase in number of cases or of improved detection? A recent study in the USA showed a significant decrease in tumour size over time and concluded that the apparent increase in TC incidence was largely due to more detection of non-symptomatic tumours (Kent et al. 2007). It has been shown that TC can exist as subclinical entity since at least one-third of the adults have subclinical TC at autopsies (Harach et al. 1985). Improved detection by the increased use of and improved (resolution of) diagnostic tools and medical surveillance might be responsible for the detection of more subclinical disease and could also have resulted in a shift in detection from more advanced tumours to early-stage tumours. Nevertheless, incidence rates also increased for T3 TC, and this increase was larger than the decrease in incidence rates of T4 TC. This increasing trend might be less related to the improved detection and increased surveillance. True increases in incidences of TC have been associated with different risk factors like exposure to ionising radiation (fallout, diagnostic tests like computed tomography scans and treatments like radiotherapy), low iodine intake (Liu et al. 2009, Ceresini et al. 2012) and overweight (Kitahara et al. 2011).

However, none of these factors have been proven as risk factors in The Netherlands. Therefore, more research into the events involved in the initiation and progression of TC is needed.

Five-year relative survival rates for differentiated TC (papillary or follicular) were high and within the range of rates described for the USA (Yu et al. 2010) and Europe (Verdecchia et al. 2007). The small differences suggest corresponding differences in the availability of diagnostic and treatment options, and in the effectiveness of health care systems. The non-significant decrease in 5-year relative survival rates for T4 TC could be explained by the decrease in the incidence of the slowly growing T4 TC,
indicating that those tumours are earlier detected as T3 TC. Furthermore, since 2002 any tumour with minimal extrathyroidal extension is registered as T3 instead of T4 TC and all anaplastic tumours are registered as T4 TC, leaving the truly advanced cancers with a worse prognosis as T4 TC, which could explain the decrease in survival rates for these tumours.

Five-year relative survival rates for anaplastic (5.6–11.4% depending on race) and medullary cancer (73.5–88.7% depending on race) were higher is the USA compared with The Netherlands (Yu et al. 2010). The low incidence rates of both tumours have limited the development of clinical expertise and conduction of randomised clinical trials (Kloos et al. 2009). The American Thyroid Association recently came up with evidence-based management guidelines for medullary (Kloos et al. 2009) and anaplastic TC (Smallridge et al. 2012). Dissemination of standardised guidelines to Europe is important to ensure optimal treatment for these patients. Recently, a study showed improved disease-specific survival for a subpopulation of anaplastic TC patients who were treated by aggressive multimodal regimes based on a prognostic index (Orita et al. 2011). Application of this prognostic index in The Netherlands could possibly lead to some improvements in survival rates for this most lethal tumour.

The increased incidence of TC was not accompanied by a concurrent increase in TC mortality which even decreased for both men and women, equal to other studies in Europe (Pacini et al. 2010) and the USA (Sipos & Mazzaferr 2010). Many of the detected tumours were indeed small treatable cancers. The detection of these small tumours could have preceded development of more advanced cancers (T4 TC) or tumours with more unfavourable prognosis such as medullary and anaplastic cancers whose incidence remained stable and whose prognosis slightly decreased.

Since a large part of the increased incidence in our study can be ascribed to the detection of small (sub-clinical) tumours, overdiagnosis of clinically irrelevant cancer might be occurring (Welch & Black 2010). Indeed, most patients with cytological indeterminate nodules are referred for diagnostic thyroid surgery, but the majority (66%) prove to have benign disease (Wang et al. 2011) and for these patients surgery is unnecessary (Alexander et al. 2012).

It has been hypothesised that increased detection of low-risk tumours can lead to an overestimation of treatment efficacy and a subsequent rise in use of treatment (Haymart et al. 2011). Up to now, there is a lack of randomised controlled trials to support management decisions for small and low-risk tumours. For patients with early-stage differentiated TC whose primary tumour is >1 cm the guidelines recommend total thyroidectomy and radioactive iodine treatment to be selectively considered (Pacini et al. 2010). Nevertheless, treatment with radioactive iodine is of uncertain benefit for patients with low-risk disease (Schwartz et al. 2012). In addition, the majority of patients with early-stage differentiated TC will have a favourable outcome and many of these tumours would remain asymptomatic during lifetime (Pacini 2012) However, a small proportion of these patients will experience recurrent disease with increased morbidity (Momesso et al. 2012). There is a need to improve the pre-operative evaluation of low-risk thyroid nodules in order to prevent potential overtreatment and in addition to this a more conservative surgical approach without radioiodine therapy should be considered for low-risk patients (Momesso et al. 2012). A complete understanding of the various prognostic factors is important to advise the patient accordingly on the best treatment and long-term surveillance (Sipos & Mazzaferr 2010). This is important since we recently showed that problems and symptoms of TC and its treatment can be detected up to 20 years after diagnosis (Husson et al. 2013). These late symptoms were mostly related to thyroid dysregulation (neuromuscular, concentration, sympathetic, psychological and sensory problems) and not so much to specific morbidities as a consequence of surgery (voice problems, throat/mouth problems and problems with scar). Long-term health problems are becoming more important since the prevalence of TC survivors who received more or less aggressive/invasive treatment is increasing and will probably lead to an increased burden on health care in the coming years.

Figure 4
Three-year moving average of age-standardised mortality rates of TC in The Netherlands 1989–2009 according to gender and age group at diagnosis.
By combining the three epidemiologic determinants of TC burden (i.e. incidence, mortality and survival) with essential prognostic determinants we achieved a more comprehensive assessment of the progress against TC, however also quality of life assessments should be added (Husson et al. 2011). Some limitations of this study require consideration. Despite the rather clinical nature of the NCR, lack of details regarding applied primary treatments in our population-based registry limited the potential to explore and elucidate specific reasons for the observed changes in survival. Furthermore, since the TNM staging system changed significantly in 2002, and the NCR did not provide us with information on the exact tumour size, it was impossible to use a uniform staging system for our analyses, which hampered the interpretation of our results.

In conclusion, TC detection and incidence has been rising in The Netherlands, while mortality rates are decreasing and survival rates remained stable and appeared to be somewhat higher except for advanced tumours of which the frequency decreased markedly.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This study was performed as part of the project ‘Progress against cancer in The Netherlands since the 1970’s’ (Dutch Cancer Society Grant EMCR 2006-3489). The study sponsors had no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. We are grateful for the dedicated data collection by the various registration teams of the Netherlands Cancer Registry.

Author contribution statement
O Husson, H R Haak, LV van de Poll-Franse and JW W Coebergh contributed to the concept and design of the study. H Karim-Kos contributed to the acquisition of the data. O Husson and L N van Steenbergen analysed the data. O Husson drafted the manuscript. All authors (O Husson, H R Haak, L N van Steenbergen, W-A Nieuwlaat, B A C van Dijk, G A P Nieuwenhuijzen, H Karim-Kos, J L Kuijpers, L V van de Poll-Franse and J W W Coebergh) provided input to the manuscript and have approved the final manuscript.

References


Ederer F & Heise H 1959 Instructions to IBM 650 programmers in processing survival computations. Bethesda, MD, USA: National Cancer Institute.


Received in final form 13 February 2013
Accepted 25 February 2013
Made available online as an Accepted Preprint 26 February 2013